Compounded vs FDA-Approved GLP-1s: What You Should Know
Compounded GLP-1s were everywhere during the shortage years. Here’s what changed, how they differ from FDA-approved products, and what to ask before you inject anything.
Will Insurance Cover GLP-1 Medications? A Practical Guide to Prior Authorizations, Appeals and Alternatives
A physician’s practical guide to insurance coverage for semaglutide and tirzepatide: what plans look for, prior authorization tips, Medicare rules and appeals.
The first call many patients make after deciding to try a GLP-1 medication isn’t to a doctor. It’s to their insurance company — and they often hang up more confused than before. One representative says the drug is covered; the pharmacy says it needs prior authorization; the prior authorization is denied for reasons no one explains.
I have an MBA alongside my medical training, and I’ve spent a lot of time untangling this process. Below is the practical version: why coverage varies so much, what insurers usually ask for, how Medicare differs, and what to do if the answer is no.
Why coverage is so inconsistent
Semaglutide and tirzepatide are each sold under different brand names for different approved uses. The same molecule may be covered when prescribed for type 2 diabetes and excluded when prescribed for weight management. Coverage depends on three things:
- Your plan’s benefit design. Many employer plans simply exclude weight-management drugs as a category. Others cover them with conditions.
- The approved indication. Diabetes, weight management, cardiovascular risk reduction and obstructive sleep apnea are separate labeled uses, and plans treat them differently.
- Your documentation. Even when a drug is covered, the plan usually requires proof that you meet its criteria.
What insurers typically look for
For weight-management indications, the FDA labeling applies to adults with a body mass index of 30 or higher, or 27 or higher with at least one weight-related condition such as high blood pressure, high cholesterol, prediabetes or sleep apnea. Plans usually mirror those criteria and may add their own, such as:
- A documented BMI within a recent window, sometimes with a baseline weight.
- Evidence of participation in a lifestyle or nutrition program.
- Prior trial of an older, less expensive medication (“step therapy”).
- Follow-up proof of weight loss — often a set percentage after several months — to renew approval.
This is where good records help. A clinician who documents your history, your measurements, your lab results and your related conditions gives the prior authorization its best chance.
Medicare and government plans
Federal law has long allowed Medicare Part D plans to exclude drugs used for weight loss. That has historically meant most Medicare beneficiaries could not get a GLP-1 covered for weight alone. The picture has become more nuanced as the approved uses have expanded:
- In 2024, the FDA approved semaglutide to reduce the risk of major cardiovascular events in adults with established cardiovascular disease and obesity or overweight. That indication is not “weight loss,” and some Part D plans cover it on that basis.
- Later in 2024, tirzepatide was approved for moderate to severe obstructive sleep apnea in adults with obesity, which has opened another route for some patients.
Federal policy on Medicare coverage for obesity medications has been under active discussion, so I encourage patients to check the current year’s plan documents rather than relying on what a friend was told last year. Manufacturer savings cards generally cannot be used with Medicare or Medicaid.
If the answer is no
- Ask for the denial reason in writing. Is it a plan exclusion, or missing documentation? Only the second can usually be fixed.
- Request a formulary check. Sometimes a different product on the plan’s preferred list is covered.
- File an appeal when the denial is about criteria you actually meet. Your prescriber can submit a letter of medical necessity.
- Ask your employer’s benefits office. Coverage decisions are often made at the employer level, and some employers add coverage when enough employees ask.
- Review self-pay options. Manufacturers have introduced direct-pay programs for some products, and HSA or FSA funds can often be used for prescribed medications. Current costs are best reviewed at a visit or on our pricing page.
A word of caution about cheap shortcuts
A denial can make unregulated online sellers tempting. Products sold without a prescription or labeled “for research use” carry real risk of the wrong substance or dose. Coverage frustrations are real, but they aren’t worth an emergency room visit. And these medications are not right for everyone: people with a personal or family history of medullary thyroid cancer, a history of pancreatitis, or who are pregnant or planning pregnancy need a different plan.
Frequently asked questions
Does having diabetes change coverage?
Often, yes. Plans that exclude weight-management drugs frequently cover GLP-1 medications for type 2 diabetes when criteria are met.
How long does prior authorization take?
It varies from a day or two to a few weeks. Complete documentation up front usually speeds the process.
Will my coverage continue after I lose weight?
Many plans require renewal with proof of progress. Keep your follow-up visits so your records reflect your results.
Can I use HSA or FSA funds?
Prescribed medications are generally eligible, but confirm with your plan administrator.
Start with a clear plan
Our medical weight loss program starts with a complimentary, no-commitment consultation where we review your history, discuss medication options and talk through realistic coverage and self-pay paths.
- Hudson, OH: 50 W Streetsboro St, Suite 2 · (330) 460-5915
- Barboursville, WV: 1 Chateau Grove Ln · (304) 520-0461
Ask about Easy Pay financing.
References: Social Security Act, Section 1927(d)(2), agents that may be excluded from coverage, including those used for weight loss. · Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023. · Malhotra A, et al. Tirzepatide for the treatment of obstructive sleep apnea and obesity. New England Journal of Medicine. 2024.
This article is for general information only and is not medical advice. Treatments are provided only after consultation and evaluation by a licensed provider. Individual results vary.
About the authorDr. Robin Arora, MD, MBA is the founder and medical director of Serene Med Spa and a Biote Certified Provider. He is board-certified in internal medicine, nephrology and hypertension, and addiction medicine, and in aesthetic medicine through the American Academy of Aesthetic Medicine (AAAM).
More from The Serene Journal
All articles →